No abstract

No abstract

S15cohorts. Median overall survival was 9.56 months in the CPX-351 arm and 5.95 months in the 7+3 arm (hazard ratio, 0.69 [95% CI, 0.52-0.90]; 1-sided P = 0.003). By 2 years, 84% of patients in the 7+3 arm had died versus 67% in the CPX-351 arm. Thus, on average, for every 6 patients treated with CPX-351, 1 death would be prevented over 2 years compared with 7+3 (1/(0.84 -0.67)). The CPX-351 safety profile was consistent with the known profile of 7+3. ConCluSionS: CPX-351 improved survival versus 7+3, with an associated NNT of 6 to prevent 1 death at 2 years, supporting the treatment benefit of CPX-351 in adults with newly diagnosed, tAML/AML-MRC.

No abstract

No abstract